SAILONG PHARMACEUTICAL GROUP CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.08 CNY | +4.02% |
|
+9.21% | -27.85% |
| 04-19 | Sailong Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-08 | Sailong Pharmaceutical Group Co.,Ltd. Approves Board Elections | CI |
| Sales 2022 | 264M 36.53M 49.87M | Sales 2023 | 311M 42.96M 58.64M | Capitalization | 2.46B 340M 464M |
|---|---|---|---|---|---|
| Net income 2022 | -37M -5.12M -6.98M | Net income 2023 | 9M 1.24M 1.7M | EV / Sales 2022 | 8.36 x |
| Net Debt 2022 | 71.16M 9.84M 13.43M | Net Debt 2023 | 47.86M 6.62M 9.03M | EV / Sales 2023 | 8.07 x |
| P/E ratio 2022 |
-57.3
x | P/E ratio 2023 |
258
x | Employees | 464 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 34.27% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.02% | ||
| 1 week | +9.21% | ||
| Current month | -9.92% | ||
| 1 month | -9.76% | ||
| 3 months | -21.37% | ||
| 6 months | -20.75% | ||
| Current year | -27.85% |
1 week
9.04
10.10
1 month
8.8212.07
Current year
7.7014.35
1 year
7.7020.02
3 years
7.7020.02
5 years
7.4420.02
10 years
7.4431.05
| Managers | Title | Age | Since |
|---|---|---|---|
Chi Nong Cai
CEO | Chief Executive Officer | 51 | 02-04-02 |
Jing Gao
DFI | Director of Finance/CFO | 48 | 13-07-31 |
Jian Feng Li
CTO | Chief Tech/Sci/R&D Officer | 43 | 07-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nan Gui Cai
FOU | Founder | 62 | 02-04-02 |
Chi Nong Cai
CEO | Chief Executive Officer | 51 | 02-04-02 |
Lin Tang
BRD | Director/Board Member | 50 | 04-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-28 | 10.08 | +4.02% | 3 741 110 |
| 24-04-26 | 9.69 | +0.10% | 3,128,060 |
| 24-04-25 | 9.68 | +1.89% | 3,827,960 |
| 24-04-24 | 9.5 | +0.42% | 3,169,700 |
| 24-04-23 | 9.46 | +5.58% | 4,477,080 |
End-of-day quote Shenzhen S.E., April 28, 2024
More quotes
Sailong Pharmaceutical Group Co Ltd, formerly Zhuhai Sailong Pharmaceutical Co Ltd, is a China-based company principally engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations, as well as providing technical services. The Companyâs main products include monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others. Through its subsidiaries, the Company is also engaged in the sales of scraps, provision of technical services and sales promotion. The Company mainly conducts its businesses with domestic market.
Sector
Pharmaceuticals
Calendar
2024-05-16
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -27.85% | 235M | |
| +20.81% | 43.34B | |
| +20.44% | 21.96B | |
| +13.30% | 14.09B | |
| +12.97% | 13.64B | |
| +39.74% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 002898 Stock
